Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by CEL-SCI Corporation

< Previous 1 2 3 4 Next >

CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer

April 19, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension

March 08, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology

March 03, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results

February 15, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments

December 28, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Issues Letter to Shareholders

November 22, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment

October 17, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer

September 12, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Issues Letter to Shareholders

September 07, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov

August 19, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results

August 15, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

August 08, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Announces Reddit AMA with Geert Kersten

July 14, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation to Present at LD Micro Invitational

June 08, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO

June 07, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Publication of ASCO 2022 Abstracts

May 27, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results

May 16, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Acceptance of Abstracts to ASCO 2022

April 22, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results

February 14, 2022

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments

December 22, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility

October 22, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results

August 16, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Issues Letter to Shareholders

July 07, 2021

From CEL-SCI Corporation

Via Business Wire

Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available

July 02, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

June 30, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study

June 28, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting

June 25, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering

June 11, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million

June 08, 2021

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Bought Deal Offering

June 08, 2021

From CEL-SCI Corporation

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by CEL-SCI Corporation

Starting at /week.